Hepatic and Intestinal Immunobiology Group, Departamento de Medicina Clínica, Universidad Miguel Hernández, San Juan de Alicante, Spain.
IIS ISABIAL, Hospital General Universitario Dr. Balmis, Alicante, Spain.
Liver Int. 2024 Apr;44(4):996-1010. doi: 10.1111/liv.15836. Epub 2024 Jan 31.
We evaluated tolerogenic C-type lectin LSECtin loss in cirrhosis and its potential regulation by cytokines.
Liver tissue from patients with cirrhosis and healthy controls, immortalised and generated LSECtin-CRISPR immortalised LSECs, and murine primary LSECs from the CCl model were handled.
LSECtin expression was reduced in liver tissue from cirrhotic patients, and it decreased from compensated to decompensated disease. Increased phosphorylation of MAPK, Akt and NFkB was observed upon LSECtin stimulation in LSEC murine cell line, showing a pattern of inflammatory and chemotactic cytokines either restrained (IL-10, CCL4) or unrestrained (TNF-α, IL-1β, IL-6, CCL2). CD44 attenuated whereas LAG-3 increased all substrates phosphorylation in combination with TLR4 and TLR2 ligands except for NFkB. TNF-α, IL-1 β, IL-6 and CCL2 were restrained by LSECtin crosslinking on TLRs studied. Conversely, IL-10 and CCL4 were upregulated, suggesting a LSECtin-TLRs synergistic effect. Also, LSECtin was significantly induced after IL-13 stimulation or combined with anti-inflammatory cytokines in cirrhotic and immortalised LSECs. Th17 and regulatory T cells were progressively increased in the hepatic tissue from compensated to decompensated patients. A significant inverse correlation was present between gene expression levels of CLEC4G/LSECtin and RORγT and FOXP3 in liver tissues.
LSECtin restrains TLR proinflammatory secretome induced on LSECs by interfering immune response control, survival and MAPKs signalling pathways. The cytokine-dependent induction of LSECtin and the association between LSECtin loss and Th17 cell subset expansion in the liver, provides a solid background for exploring LSECtin retrieval as a mechanism to reprogram LSEC homeostatic function hampered during cirrhosis.
我们评估了肝硬化中耐受型 C 型凝集素 LSECtin 的缺失及其潜在的细胞因子调节作用。
处理了肝硬化患者和健康对照者的肝组织、永生化的 LSECtin-CRISPR 永生化 LSECs,以及来自 CCl 模型的小鼠原代 LSECs。
肝硬化患者肝组织中 LSECtin 的表达减少,并且从代偿期到失代偿期疾病时其表达降低。在 LSEC 小鼠细胞系中,LSECtin 刺激后观察到 MAPK、Akt 和 NFkB 的磷酸化增加,表现出炎症和趋化性细胞因子的模式,要么受到抑制(IL-10、CCL4),要么不受抑制(TNF-α、IL-1β、IL-6、CCL2)。CD44 减弱而 LAG-3 增加所有底物的磷酸化,与 TLR4 和 TLR2 配体结合,除 NFkB 外。TLRs 研究中,LSECtin 交联可抑制 TNF-α、IL-1β、IL-6 和 CCL2。相反,IL-10 和 CCL4 上调,表明 LSECtin-TLRs 协同作用。此外,在肝硬化和永生化 LSECs 中,IL-13 刺激或与抗炎细胞因子联合后,LSECtin 显著诱导。从代偿期到失代偿期患者,肝组织中 Th17 和调节性 T 细胞逐渐增加。在肝组织中,CLEC4G/LSECtin 的基因表达水平与 RORγT 和 FOXP3 呈显著负相关。
LSECtin 通过干扰免疫反应控制、存活和 MAPKs 信号通路,抑制 LSECs 上 TLR 促炎分泌。LSECtin 的细胞因子依赖性诱导及其在肝脏中与 Th17 细胞亚群扩增的相关性,为探索 LSECtin 回收作为一种恢复肝硬化期间受损的 LSEC 稳态功能的机制提供了坚实的基础。